

6. Robinson DA, Tanaka N, Fece de la Cruz F. Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers. *Cancer Discov.* 2024;14:727-736.

7. Shih C, Weinberg RA. Isolation of a transforming sequence from a human bladder carcinoma cell line. *Cell.* 1982;29:161-169.

8. Goldfarb M, Shimizu K, Percho M, et al. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. *Nature.* 1982;296(5856):404-409.

9. Pulciani S, Santos E, Lauver AV, et al. Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells. *Proc Natl Acad Sci U S A.* 1982;79:2845-2849.

10. Lièvre A, Bachet JB, Le Corre D. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. *Cancer Res.* 2009;66:3992-3995.

11. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature.* 2012;486:532-536.

12. Neumann J, Zeindl-Eberhart E, Kirchner T, et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. *Pathol Res Pract.* 2009;205:858-862.

13. Sorich MJ, Wiese MD, Rowland A, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. *Annals of Oncology.* 2015;26:13-21.

14. Lu S, Jang H, Nussinov R, et al. The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B. *Scientific Reports.* 2016;6(1):1-15.

15. Huang L, Guo Z, Wang F, et al. KRAS mutation: from undruggable to druggable in cancer. *Signal Transduction and Targeted Therapy.* 2021;6(1):1-20.

16. Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. *Nature.* 2013;503:548.

17. Janes MR, Zhang J, Li LS, Hansen R, et al. Targeting KRAS

Mutant Cancers with a Covalent G12C-Specific Inhibitor. *Cell.* 2018;172:578-589.e17.

18. Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature.* 2019;575:217-223.

19. Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. *Cancer Discov.* 2020;10:54-71.

20. Strickler JH, Yoshino T, Stevinson K, et al. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review. *Oncologist.* 2023;28:E981-E994.

21. Henry JT, Coker O, Chowdhury S, et al. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. *JCO Precis Onco.* 2021;5:613-621.

22. Fakih M, Tu H, Hsu H, et al. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p. G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer. *Oncologist.* 2022;27:663-674.

23. Hong DS, Fakih MG, Strickler JH, et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. *N Engl J Med.* 2020;383:1207-1217.

24. Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (Code-Break100): a prespecified analysis of a single-arm, phase 2 trial. *Lancet Oncol.* 2022;23:115-124.

25. Ou SI, Jänne PA, Leal TA, et al. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1). *J Clin Oncol.* 2022;40:2530-2538.

26. Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. *N Engl J Med.* 2023;388:44-54.

27. Purkey H. Abstract ND11: Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers. *Cancer*

Res. 2022;82:ND11-ND11.

28. Sacher A, LoRusso P, Patel MR, et al. Single-Agent Divar-sib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. *N Engl J Med.* 2023;389:222.

29. Amodio V, Yaeger R, Arcella P, et al. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. *Cancer Discov.* 2020;10:1129-1139.

30. Kuboki Y, Fakih M, Strickler J, et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. *Nat Med.* 2024; 30:265-270.

31. Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. *N Engl J Med.* 2023;389:2125-2139.

32. Fakih M, Salvatore L, Esaki T, et al. Overall survival (OS) of phase 3 CodeBreak 300 study of sotorasib plus panitumumab (soto+pani) versus investigator's choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC). *Journal of Clinical Oncology.* 2024;42:LBA3510-LBA3510.

33. Desai J, Alonso G, Kim SH, et al. Divar-sib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. *Nature Medicine.* 2023;30(1):271-278.

34. Wei D, Wang L, Zuo X, et al. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. *Clin Cancer Res.* 2024;30:655.

35. Kim D, Herdeis L, Rudolph D, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. *Nature.* 2023;619:160-166.

36. Arbour KC, Puneekar S, Garrido-Laguna I, et al. 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). *Annals of Oncology.* 2023;34:S458.

37. Wasko UN, Jiang J, Dalton TC, et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. *Nature.* 2024;629:927-936.

Připravujeme do příští Onkologie

2025

2

HLAVNÍ TÉMA – NOVINKY V LÉČBĚ UROTELIÁLNÍHO KARCINOMU

- Role imunoterapie v léčbě metastatického uroteliálního karcinomu
- Neoadjuvantní terapie karcinomů močového měchýře
- Současné možnosti adjuvantní léčby uroteliálních karcinomů
- Radioterapie jako orgán záchovný postup v léčbě invazivního karcinomu močového měchýře

PŘEHLEDOVÉ ČLÁNKY

- Hypersenzitivní lékové reakce a desenzitizace v onkologii
- Žilní vstupy v onkologii – volba mezi PICC a portem

SDĚLENÍ Z PRAXE

- Pacient s metastazujícím slizničním melanomem léčený imunoterapií
- Manažment epiteloidního inflamatorného myofibroblastického sarkómu plicného původu

Přinášíme také zajímavá supplementa, nové publikace a mnoho dalších zajímavostí z oboru ...

▼
VYCHÁZÍ
V
KVĚTNU

 **SOLEN**
let s vámi